Piper Jaffray Transitions Rating on AtriCure (ATRC) to Underweight; Risk/Reward Less Attractive
More News related to ATRC
- Piper Jaffray Upgrades AtriCure (ATRC) to Neutral; DoJ Resolution Clearly a Positive
- Relator's Attorneys Comment On AtriCure/DOJ Proposed Settlement
- Atricure (ATRC) Posts Q3 adj.-Loss of $0.06, Beats by 3c
- AtriCure Reports Third Quarter 2009 Financial Results
- AtriCure Announces Tentative Settlement with the Department of Justice
Piper Jaffray & Co. transitions rating on AtriCure (Nasdaq: ATRC) to Underweight.
Piper analyst says, "We now rate AtriCure Underweight given that its risk/reward profile appears less attractive than its peers. Relative to our target price of $4.00, the stock still offers 10%+ potential appreciation. However, with the risk associated with the ongoing Department of Justice investigation, we'd like to see a greater reward potential...With the stock valued at roughly 1x our C10 revenue estimate, it trades at a discount to other small cap cardiology companies. Under normal circumstances, we'd argue that companies competing in the AF space could trade at a premium to the group given the growth prospects in the space. But in this instance, we think a discount is warranted given the uncertainty tied to the ongoing DOJ investigation...DOJ Investigation Continues To Be An Overhang."
To see more analyst ratings on ATRC Click Here.
AtriCure, Inc. is a medical device company that develops, manufactures and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue.
Related Categories
DowngradesNew Coverage
Stocks Mentioned
-0.12Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
